Lifecore Biomedical에 대한 매도 수량은 투자자에게 Lifecore Biomedical의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Lifecore Biomedical (NASDAQ:LFCR) 주식, 공매도 수량 보고

Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

APOG

LFCR

MMLP

UAVS

금요일 오전 (현지 시간 기준) 미국 주가 지수 선물이 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 아포지 엔터프라이즈(NASDAQ:APOG)가 분기 이익을 주당 1.23달러, 매출 3억 3,529만 달러로 예상하고 있다. 아포지의 주식은 애프터 마켓에서 0.1% 상승하여 68.50달러에 거래되었다.

금요일 주목해야 할 주식: 아포지 엔터프라이즈, 스마트 샌드 그리고 3종목

Lifecore Biomedical Inc

BingEx Limited ("BingEx" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>), a leading on-demand dedicated courier services provider in China (branded as "FlashEx"), today announced the pricing of its initial public offering of 4,000,000 American Depositary Shares ("ADSs"), each representing three Class A ordinary shares of the Company, at US$16.50 per ADS. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to total US$66.0 million, assuming the underwriters do not exercise their option to purchase additional ADSs. In addition, BingEx has granted the underwriters a 30-day option to purchase up to an aggregate of 600,000 additional ADSs at the initial public offering price less underwriting discounts and commissions.
The ADSs have been approved for listing and are expected to begin trading on the Nasdaq Stock Market today under the symbol "FLX." The offering is expected to close on October 7, 2024, subject to customary closing conditions.
Deutsche Bank Securities Inc., China International Capital Corporation Hong Kong Securities Limited, and CLSA Limited are acting as the representatives of the underwriters.

IPOs

BingEx Limited Announces Pricing Of $66M Initial Public Offering Of 4M ADSs At a Price OF $16.50/ADS

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says External Shocks Have Derailed Many A Soft Landing In Previous Times

UXIN

Uxin Shares Resume Trade Following Circuit Breaker Halt

Fed's Goolsbee Says We Are Transitioning From A Focus On Cutting Inflation Rate To A More Balanced Approach; Says We Will Have Discussions About What Rate We Need To Ultimately Need To Settle On

Fed's Goolsbee Says By End Of 2025 I Think Policy Rate Will Be A Fair Bit Lower, If Conditions Continue Like This; Says We'll Get A Bunch More Data Before Next Fed Meetings; Says Our Goal Is To Keep Inflation, Unemployment Almost Exactly Where They Are Right Now

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Truist Securities analyst Jake Bartlett maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Buy and raises the price target from $196 to $202.

Price Target

Analyst Ratings

TXRH

Truist Securities Maintains Buy on Texas Roadhouse, Raises Price Target to $202

Fed's Goolsbee Says Powell's Message That There Are Balanced Risks Is Wise And Exactly How We Should Think About This

Truist Securities analyst Mark Hughes maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Hold and raises the price target from $65 to $80.

GSHD

Truist Securities Maintains Hold on Goosehead Insurance, Raises Price Target to $80

Fed's Goolsbee Says Don't Get Too Worked Up About Any One Month's Report; Says The More Reports Like This, The More Confident I'd Be That Labor Market Is Where We Want To Be

Scotiabank analyst Phil Hardie upgrades Propel Holdings (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PRL#TSX">PRL</a>) from Sector Perform to Sector Outperform and raises the price target from C$28 to C$34.

Upgrades

TSX:PRL

Scotiabank Upgrades Propel Holdings to Sector Outperform, Raises Price Target to C$34

U.S. stocks were higher, with the Dow Jones index gaining more than 50 points on Friday.
Shares of Apogee Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APOG#NASDAQ">APOG</a>) rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS<a href="https://www.benzinga.com/news/earnings/24/10/41182821/architectural-services-company-apogee-smashes-q2-expectations-hikes-fy25-eps-outlook-despite-revenu"> guidance above estimates</a>.
Apogee Enterprises reported second-quarter sales of $342.4 million, beating the consensus estimate of $335.3 million. Adjusted EPS rose 5.9% Y/Y to $1.44, beating the consensus of $1.23.
Apogee Enterprises shares jumped 20.7% to $82.56 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Frontier Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) gained 20.6% to $6.02 following a report suggesting Spirit Airlines is considering filing for bankruptcy. The company, a budget airline, may see a rise in passengers due to a drop in competition.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) surged 15% to $7.34 following a report suggesting Sprint Airlines is considering filing for bankruptcy. Earlier this year, a judge blocked a merger between the two companies because it could hurt competition and hike ticket prices.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) surged 12.5% to $3.8250.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) gained 11.8% to $19.08 after the company announced it will present its long-term data from the HOPE-2 open-label extension study at the 2024 World Muscle Society Congress.</li>
<li>Arcadium Lithium plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) rose 10.5% to $3.0950.</li>
<li>Barnes Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>) gained 10.3% to $44.22 following a report suggesting that Apollo Global Management is in talks to acquire the company.</li>
<li>JinkoSolar Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) shares rose 10.3% to $28.84.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) gained 7.2% to $20.33 after Citigroup initiated coverage on the stock with a Buy rating and announced a price target of $26.8.</li>
<li>V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) gained 6.6% to $20.81.</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) climbed 6% to $142.21.</li>
<li>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) gained 5.1% to $58.48.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41184411/this-morgan-stanley-analyst-turns-bullish-here-are-top-5-upgrades-for-friday">This Morgan Stanley Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday</a></li>
</ul>

Intraday Update

Movers

ALTM

CAPR

JBLU

MNSO

ULCC

Apogee Enterprises Posts Upbeat Earnings, Joins Frontier Group, JetBlue Airways And Other Big Stocks Moving Higher On Friday

Have you ever walked into a dispensary, asked a budtender for advice and left wondering if they had any idea what you were talking about or needed? In an exclusive interview with Benzinga Cannabis, Martez Knox, founder and CEO of BakedBot AI, shared info on AI-driven bots are changing customer experiences and B2B transactions by making sure you get the right product every time. 
BakedBot AI launched in January 2023, but Knox's journey with AI began earlier when he worked in marketing automation and lead generation. 
Frustration with the budtender's lack of knowledge sparked the idea to leverage AI for more personalized cannabis recommendations.&nbsp;
&#8220;The idea hit me when I realized that the budtender had no clue what would work best for me as a customer,&#8221; Knox said. With advanced AI tools, his systems are boosting efficiency, sales and customer retention for dispensaries.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Solving Dispensary Pain Points With AI</h3>
Knox identified several pain points in the cannabis industry, particularly the challenge of reaching customers through marketing channels.&nbsp;
"Bigger carriers like Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) and T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) often block messages containing certain words, making it difficult for dispensaries to connect with customers," <a href="https://www.linkedin.com/in/martezknox/">Martez</a> noted, adding that <a href="https://www.linkedin.com/company/bakedbot-ai/">BakedBot AI </a>addresses that issue. How? By using AI-powered autonomous agents that streamline customer engagement while improving outreach without relying on expensive marketing agencies.
One of BakedBot's flagship products, Smokey, the AI budtender, plays a crucial role in <a href="https://www.benzinga.com/topic/cannabis-marketing">personalizing</a> customer experience. 
Smokey uses customers&#8217; purchase histories and other data points to recommend strains based on individual preferences, from terpene profiles to personal preferences. 
&#8220;We're keeping their customers happy, lowering acquisition costs, and increasing lifetime value (LTV),&#8221; Knox explained, underscoring how AI-driven personalization enhances customer loyalty and reduces business costs.
Beyond personalization, Knox emphasized that BakedBot AI is designed to streamline daily operations for dispensaries, helping reduce losses and optimize workflow. Companies have found that after implementing AI tools, they can automate tasks such as price tracking against local competitors.&nbsp;
&#8220;We've saved marketers hours by automating the process of gathering competitor data,&#8221; Knox explained, highlighting how AI-powered tools enable businesses to maintain competitive pricing strategies without the need for manual input.
BakedBot's AI also help dispensaries optimize shelf space by analyzing sales trends and <a href="https://www.benzinga.com/markets/cannabis/24/10/41176039/whats-the-difference-between-medical-and-recreational-cannabis-users-new-survey-reveals-market-t">customer preferences</a>. 
&#8220;We help owners determine which products should be discounted and which should remain at full price, based on real-time market data and customer demand,&#8221; Knox said. 
These tools not only prevent losses from overstocking slow-moving products but also help maximize profitability by focusing on top-selling items.
Read Also:<a href="https://www.benzinga.com/general/biotech/24/08/40298228/think-you-can-do-it-all-20-000-reasons-why-automation-outperforms-a-broad-approach-in-cannabis">&nbsp;Think You Can Do It All? 20,000 Reasons Why Automation Outperforms A Broad Approach In Cannabis</a>
<h3 class="wp-block-heading">Creating Buyer Archetypes With AI</h3>
One of the key advantages of BakedBot AI is its ability to create detailed buyer archetypes. &#8220;AI is great at finding patterns in big data,&#8221; he said. &#8220;We look at <a href="https://www.benzinga.com/markets/cannabis/24/08/40533363/how-seo-trauma-is-costing-weed-brands-70-of-sales-and-why-most-dispensaries-fail-jp-donahue-unle">thousands of data points</a> to predict customer behavior, whether it&#8217;s a college student on a budget or a more established adult seeking specific effects.&#8221; This ability to build <a href="https://www.benzinga.com/markets/cannabis/24/06/39540101/budget-conscious-consumers-boost-sales-of-marijuana-multipacks-94-brands-vie-for-colorados-pre-r">buyer archetypes </a>ensures that dispensaries can tailor their marketing and product offerings more effectively.
&#8220;If a customer likes OG Kush with a high percentage of certain <a href="https://www.benzinga.com/general/biotech/24/05/38626097/why-does-tangie-smell">cannabinoids and terpenes</a>, there&#8217;s a good chance they&#8217;ll enjoy a similar strain.&#8221; 
<h3 class="wp-block-heading">Integrating Local Knowledge Into AI Systems</h3>
Knox explained that BakedBot AI integrates both big data and local knowledge to create a comprehensive solution for dispensaries. &#8220;Dispensaries themselves can upload their data about local trends, customer preferences, and word of mouth into the system,&#8221; he said.&nbsp;
Read Also:<a href="https://www.benzinga.com/general/biotech/24/09/40754415/transforming-a-5-000-year-old-craft-how-weed-companies-use-data-to-make-hash-without-losing-its-a">&nbsp;Transforming A 5,000-Year-Old Craft: How Weed Companies Use Data To Make Hash Without Losing Its Art</a>
<h3 class="wp-block-heading">Lead Generation And Data Ownership</h3>
Knox says there is great potential in AI's ability to drive lead generation. &#8220;Lead generation is all about getting customers into your funnel.&#8221; BakedBot's headless menu solution allows dispensaries to optimize <a href="https://www.benzinga.com/markets/cannabis/24/09/40753138/how-google-ai-and-digital-marketing-are-changing-weed-retailing-for-good-how-you-can-and-should-">product visibility on Google</a>, driving organic traffic without relying on external platforms. 
He was clear on the importance of dispensaries owning their customer data. &#8220;Dispensaries need their <a href="https://www.benzinga.com/markets/cannabis/24/04/38230062/your-next-weed-promo-could-go-viral-how-cannacribs-is-shaping-social-media-with-influencer-marke">web presence </a>to generate first-party data. If your dispensary is using the biggest marketplaces out there, you&#8217;re not getting access to first-party data,&#8221; he said. &#8220;We provide dispensaries with the tools to gather that data directly from their websites.
&#8220;AI is all about recognizing patterns,&#8221; Knox explained. &#8220;When you look at large language models, it&#8217;s essentially predictive analytics at work—identifying which words and phrases are most likely to follow others based on huge data sets. Machine learning comes into play by enabling systems to find these patterns and learn from them, improving predictions over time.&#8221;&nbsp;
He added that with AI, &#8220;it&#8217;s more like advanced predictive analytics, helping businesses make <a href="https://www.benzinga.com/markets/cannabis/24/05/38972587/who-is-buying-marijuana-and-why-market-data-provides-behavior-profiles-insights-for-investors">decisions based on vast amounts of data t</a>hat constantly refine as new information comes in.&#8221;
<h3 class="wp-block-heading">It's Freemium </h3>
"We offer a freemium model," Knox said, noting that small operators can access a limited version of Smokey for free. This model includes basic AI-driven features, such as the budtender tool and a headless menu solution. 
For more complex needs, such as advanced automation and in-depth analytics, dispensaries can upgrade to paid plans starting at $50 per month.
&#8220;This pricing model makes AI tools affordable for smaller operators while providing larger operations with the flexibility to scale up.&#8221; 
Read Also:<a href="https://www.benzinga.com/general/biotech/23/08/33579692/cannabis-robots-meet-the-company-boosting-efficiency-and-margins-through-packaging-automation">&nbsp;Cannabis Robots: Meet The Company Boosting Efficiency And Margins Through Packaging Automation</a>
<h3 class="wp-block-heading">Meet The Bot </h3>
Knox said he&#8217;s confident the company will further disrupt cannabis retail. "We expect to be out of beta in a month or two," he said, hinting at future developments that could further enhance the dispensary experience.
BakedBot AI will be at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> in Chicago on October 8-9, 2024. Investors can check out how their AI tools drive critical improvements in margins, cost of goods, and shelf optimization through predictive analytics. 
With over 2,000 attendees and 200 investors expected, it&#8217;s a prime opportunity to see how AI can maximize profits in cannabis retail​.&nbsp;
Read Next:&nbsp;<a href="https://www.benzinga.com/news/24/09/40941818/how-this-cheese-aging-tech-is-boosting-profits-for-cannabis-growers-stop-throwing-cheddar-out-the-do">How This Cheese-Aging Tech Is Boosting Profits For Cannabis Growers: Stop Throwing Cheddar Out The Door</a>

Biotech

Cannabis

Entrepreneurship

Retail Sales

Management

Success Stories

Small Business

Exclusives

Tech

Interview

TMUS

Budtenders Letting You Down? Meet The Weed Bot That Actually Knows What You Want

<a href="https://x.com/hntrbrkmedia/status/1842207710009237818" title="https://x.com/hntrbrkmedia/status/1842207710009237818">https://x.com/hntrbrkmedia/status/1842207710009237818</a>

Shares Of Ferroglobe Seeing Volume, Hunterbrook Post On X, "Hunterbrook Capital is long Ferroglobe Plc…"

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HSBC analyst Sean McLoughlin downgraded the rating for GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) from Buy to Hold but raised the price target from $240 to $255. GE Vernova shares gained 1% to close at $254.68 on Thursday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Eugene Hsiao downgraded Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) from Outperform to Neutral but increased the price target from $25 to $33. Li Auto shares fell 3.6% to close at $28.82 on Thursday. <a href="https://www.benzinga.com/quote/LI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Joshua Shanker downgraded the rating for Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) from Neutral to Underperform but raised the price target from $264 to $275. Chubb shares fell 1% to close at $288.54 on Thursday. <a href="https://www.benzinga.com/quote/CB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Jake Bartlett downgraded Dine Brands Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) from Buy to Hold and lowered the price target from $66 to $37. Dine Brands Global shares fell 2.9% to close at $33.55 on Thursday. <a href="https://www.benzinga.com/quote/DIN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Christopher LeFemina downgraded the rating for BHP Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) from Buy to Hold and slashed the price target from $72 to $68. BHP Group shares fell 2.5% to close at $60.89 on Thursday. <a href="https://www.benzinga.com/quote/BHP/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying LI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="520" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04090804/image-21-1024x520.png" alt="" class="wp-image-580717" style="width:571px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04090804/image-21-1024x520.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04090804/image-21-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04090804/image-21-768x390.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/04090804/image-21.png 1345w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41180069/dow-tumbles-nearly-200-points-amid-growing-middle-east-concerns-investor-optimism-declines-fear-ind">Dow Tumbles Nearly 200 Points Amid Growing Middle East Concerns: Investor Optimism Declines, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Downgrades

This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Roth MKM analyst Matt Koranda reiterates Kits Eyecare (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KITS#TSX">KITS</a>) with a Buy and maintains C$14 price target.

Reiteration

TSX:KITS

Roth MKM Reiterates Buy on Kits Eyecare, Maintains C$14 Price Target

As adult-use cannabis markets gain traction across the U.S., medical marijuana — a cornerstone of early cannabis reform — seems to be losing its place in policy discussions. 
Despite its importance, the focus on adult-use legalization has overshadowed the medical marijuana conversation, raising concerns within the industry.
Brandon Harshbarger, president of Cheech and Chong Global Holdings, discussed this shift in an interview before his appearance at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a>.
<h1 class="wp-block-heading">Medical Cannabis: The Forgotten Pillar</h1>
Harshbarger emphasized the centrality of medical marijuana in the initial stages of cannabis reform. 
&#8220;One of the things I hold most dear to my heart, and it is part of the ethos of this company, is that cannabis is medicine,&#8221; he stated. However, as recreational cannabis markets expanded, the focus on medical use diminished.
He attributed this shift, in part, to regulatory challenges posed by the FDA regarding health claims surrounding cannabis. But more importantly, he pointed to a growing market demand for casual cannabis consumption, which he believes has driven the industry's current trajectory.
&#8220;Unfortunately, when recreational programs started to take off, part of that strategy meant a reduction in emphasis on the medicinal qualities of cannabis,&#8221; Harshbarger noted. The increased access brought about by recreational markets, he explained, has made it easier for consumers to view cannabis in a more casual light, which in turn has fueled the industry's growth.
<h1 class="wp-block-heading">Balancing Access with Mission</h1>
While the industry has moved toward adult use, Harshbarger remains committed to expanding access for all medical or recreational consumers. &#8220;Our mission in cannabis is simple: access for everyone, in every market,&#8221; he said. He acknowledged that the evolution of the cannabis industry has allowed for greater availability of cannabis products. Still, he expressed concern that this shift has led to losing focus on the medical benefits that initially sparked legalization efforts.
&#8220;In some markets, that is medicinal, but in others, hemp-derived products have shown that when access to cannabis occurs at scale, the benefits are even greater than we could have ever imagined,&#8221; Harshbarger added, underscoring the potential of cannabis across all markets and forms.
<h1 class="wp-block-heading">The Road Ahead</h1>
As cannabis policy continues to evolve, Harshbarger remains hopeful that medical marijuana will regain its prominence in policy discussions. He believes that while adult-use markets are essential for industry growth, the medical cannabis community should not be forgotten. 
For Harshbarger, the future of cannabis lies in balancing both markets, ensuring that all consumers, whether casual or medical, have access to the products they need.
Photo: Courtesy of Roxana Gonzalez on Shutterstock

Events

Cheech And Chong Global Holdings President On Importance Of Medical Marijuana: 'Cannabis Is Medicine'

Roth MKM analyst Bill Kirk reiterates Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Buy and maintains $298 price target.

Roth MKM Reiterates Buy on Constellation Brands, Maintains $298 Price Target

Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) shares are moving lower on Friday following a report suggesting that the company is exploring the possibility of <a href="https://www.benzinga.com//node/41182466">filing for bankruptcy</a>.
The Details: According to the <a href="https://www.wsj.com/articles/spirit-airlines-in-talks-with-bondholders-over-terms-of-potential-bankruptcy-filing-fdd23fae">Wall Street Journal</a>, Spirit has been in talks with bondholders and creditors regarding support for a Chapter 11 bankruptcy.
This comes after a federal district court judge blocked the company&#8217;s merger with JetBlue back in January. The two airlines have abandoned the potential merger, citing that they likely could not overcome legal and regulatory challenges.
Following the ruling, Spirit has begun shrinking its operations, cutting dozens of routes for November and December. Also, the airline plans to shrink its capacity by almost 20% during the fourth quarter.
Spirit has reported losses in almost every quarter since February 2020, per data from<a href="https://www.benzinga.com/pro/"> Benzinga Pro</a>. For the 2024 fiscal-year second quarter, the company reported an adjusted net loss of $157.9 million.
Is Spirit A Good Stock To Buy?
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/SAVE">Spirit Airlines</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Spirit Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 14.96%, you'll need to buy a share of XAI Octagon FR &amp; Alt Inc by the Oct. 15, 2024. Once done, you can expect to receive a nominal payout of $0.09 on Nov. 1, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/SAVE">Spirit Airlines</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
Related Link: <a href="https://www.benzinga.com/news/24/10/41124443/whats-going-on-with-delta-united-and-spirit-airlines-shares-tuesday">What&#8217;s Going On With Delta, United and Spirit Airlines Shares Tuesday?</a>
SAVE Price Action: At the time of writing, Spirit stock is trading 26.8% lower at $1.63, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo via Wikimedia Commons

SAVE

What's Going On With Spirit Airlines Stock Friday?

Wells Fargo analyst Ken Gawrelski maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Overweight and lowers the price target from $15 to $14.

SNAP

Wells Fargo Maintains Overweight on Snap, Lowers Price Target to $14

The latest announcement is out from Lifecore Biomedical (LFCR). Ryan D. Lake has been appointed as the new Chief Financial Officer and Secretary of...

Lifecore Biomedical Welcomes Ryan Lake as New CFO

Lifecore Biomedical regains Nasdaq compliance

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Lifecore Biomedical (LFCR – Research Report). The company's sh...

Craig-Hallum Sticks to Their Buy Rating for Lifecore Biomedical (LFCR)

Barrington analyst Michael Petusky maintained a Hold rating on Lifecore Biomedical (LFCR – Research Report) today. The company's shares opened toda...

Lifecore Biomedical (LFCR) Gets a Hold from Barrington

Lifecore Biomedical ( ($LFCR) ) has shared an announcement. Lifecore Biomedical, Inc. is set to undergo changes in its Board of Directors as Jeffre...

Lifecore Biomedical Board Changes Ahead of Annual Meeting

Earnings week ahead: Nike, Carnival, Constellation Brands, and more

Lifecore Biomedical (LFCR) Receives a Buy from Craig-Hallum

Today, several major companies are expected to report earnings: Apogee (APOG) and Lifecore Biomedical (LFCR). Ahead of earnings, TipRanks shows you...

Options Volatility and Implied Earnings Moves Today, October 04, 2024

Lifecore Biomedical raises $24.3M through private placement

Lifecore Biomedical ( ($LFCR) ) has shared an update. Lifecore Biomedical, Inc. successfully closed a private placement of 5,928,775 shares of comm...

Lifecore Biomedical Raises $24.3M, Expands Capacity and Clientele

AIXI

ANGO

CALM

LEVI

MESA

MLEC

NEOV

PAYX

POCI

STBX

TRAK

UNFI

VLGEA

WKEY

Legal

Press Releases

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Penny Stocks

LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)

LFCR DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 27 Deadline in Securities Class Action – LFCR

LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Lifecore Biomedical Selected by Lindy Biosciences to Support Process Development and Commercial Scale-Up for Innovative Microglassification Formulation Technology

General

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

Financing

Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock

Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update

Comments

Lifecore Biomedical

매도 수량

Lifecore Biomedical (NASDAQ:LFCR) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌